The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 01, 2020

Filed:

Jan. 16, 2018
Applicants:

Genentech, Inc., South San Francisco, CA (US);

F. Hoffmann-la Roche Ag, Basel, CH;

Inventors:

Jennifer Eng-Wong, South San Francisco, CA (US);

Whitney Kirschbrown, South San Francisco, CA (US);

Tarik Khan, Basel, CH;

Jasper Lin, South San Francisco, CA (US);

Sreedhara Alavattam, South San Francisco, CA (US);

Amit Garg, South San Francisco, CA (US);

Sarah Heeson, Welwyn Garden, GB;

Tanja Badovinac-Crnjevic, Basel, CH;

Christine Wurth, Basel, CH;

Assignees:

GENENTECH INC., South San Francisco, CA (US);

HOFFMANN-LA ROCHE INC, Little Falls, NJ (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/20 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); A61K 9/08 (2006.01); A61K 38/47 (2006.01);
U.S. Cl.
CPC ...
A61K 9/0019 (2013.01); A61K 9/08 (2013.01); A61K 38/47 (2013.01); A61K 39/001106 (2018.08); A61K 39/39591 (2013.01); A61K 47/183 (2013.01); A61K 47/20 (2013.01); A61K 47/26 (2013.01); A61P 35/00 (2018.01); C07K 16/32 (2013.01); C12Y 302/01035 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/585 (2013.01); C07K 16/28 (2013.01); C07K 16/30 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C07K 2317/90 (2013.01);
Abstract

Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.


Find Patent Forward Citations

Loading…